In a recent phase I study, the effectiveness of an investigational 1-day aripiprazole initation regimen was found to be comparable to that of typical treatment for schizophrenia. Specifically, individuals who received the treatment—Aristada—had comparable results to those who received a 21-day initiation regimen including oral aripiprazole supplementation.
The results were recently shared at an annual meeting held by the American Psychiatric Association. It is anticipated that the new treatment will help to start individuals on medications faster, as well as reduce the complexity of their drug regimens. At this moment in time, the 1-day treatment is being reviewed for approval by the U.S. Food and Drug Administration (FDA), and a decision is expected by the end of June.
The findings were reported by David Walling, PhD, CEO and principal investigator for CNS Network (CNS). Founded in 2000, CNS has grown to become one of the largest clinical research providers in the country, and the largest in Southern California.
This was reported by Medpagetoday on May 8, 2018.
Contact Information: CNS Network, 12772 Valley View Street, Suite #3, Garden Grove, California 92845; (866) CNS-TRIAL (267-87425); Website: www.cnstrial.com